Inositol
Myo-Inositol
Vitamin-like compound that supports mood, sleep, and hormonal balance, with strong evidence for anxiety, OCD, and PCOS.
Inositol is a carbocyclic sugar naturally found in the body and in foods. It plays a key role in cell signaling, particularly in serotonin and insulin pathways. Research shows significant benefits for anxiety, OCD, panic disorder, and PCOS. Often used as a gentler alternative to or adjunct with anxiety medications.
Mechanisms of Action
Serotonin Signaling
Supports serotonin receptor function
Insulin Signaling
Supports insulin sensitivity
Cell Signaling
Critical for cellular communication
Recommended Dose
2-4g for general anxiety; 12-18g for OCD/panic
Optimal Timing
- Divided into 2-3 doses
- With or without food
Can be taken without food
Best Form
Myo-inositol powder (most economical for higher doses)
Alternatives: Capsules, D-chiro-inositol (for PCOS, in 40:1 ratio with myo)
Powder dissolves well and tastes slightly sweet. For PCOS, combination of myo-inositol and D-chiro-inositol in 40:1 ratio is optimal.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Higher doses (12-18g) for OCD/panic need to be split throughout the day. For sleep, take portion before bed.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Reduced Anxiety
Significant decrease in anxiety symptoms
OCD Symptom Improvement
Reduced obsessive thoughts and compulsions
Hormonal Balance (PCOS)
Improved ovulation and metabolic markers
GI Effects
Nausea or loose stools at high doses
Used in PCOS fertility treatment; generally considered safe
Use with caution; may trigger manic episodes
Who Should NOT Take This
- Bipolar disorder (may trigger mania at high doses)
Drug Interactions
Lithium may reduce inositol levels; supplementation may be beneficial
May have additive serotonin effects; often combined safely under supervision
Possible Side Effects
Tip: Start low and increase gradually; take with food
Tip: Reduce dose
Tip: Usually resolves with continued use
Warnings
- High doses needed for OCD/panic ā start low and titrate up
- GI side effects common initially but usually improve
- May trigger mania in bipolar disorder
Top studies from 40+ peer-reviewed papers
Motuhifonua SK et al. ā¢ The Cochrane database of systematic reviews (2023)
āEvidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth.ā
Key Findings:
- For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
- Further, myo-inositol may result in little to no difference in caesarean section (RR 0.91, 95% CI 0.77 to 1.07; 4 studies, 829 women; low-certainty evidence).
- For the secondary neonatal outcomes, meta-analysis showed no neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 4 studies; 671 infants; very low-certainty evidence).
- However, myo-inositol may be associated with a reduction in the incidence of preterm birth (RR 0.35, 95% CI 0.17 to 0.70; 4 studies; 829 infants).
Wei J et al. ā¢ Nutrients (2022)
āIn conclusion, 4 g MI nutritional supplementation per day during early pregnancy may reduce GDM incidence and severity, therefore may be a practical and safe approach for the prevention of GDM.ā
Key Findings:
- Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI).
- Compared with the control group, 4 g myo-inositol (MI) supplementation per day significantly decreased the incidence of GDM (RR = 0.30, 95% CI (0.18, 0.49), p < 0.00001).
- It also decreased the need of insulin treatment, and reduced the incidence of preterm delivery and neonatal hypoglycemia.
- However, no difference was observed between 1.1 g MI per day plus 27.6 mg D-chiro-inositol (DCI) per day and the control group regarding all evaluated results.
Showell MG et al. ā¢ The Cochrane database of systematic reviews (2020)
āIn this review, there was low- to very low-quality evidence to show that taking an antioxidant may benefit subfertile women.ā
Key Findings:
- Due to the very low-quality of the evidence we are uncertain whether antioxidants improve live birth rate compared with placebo or no treatment/standard treatment (odds ratio (OR) 1.81, 95% confidence interval (CI) 1.36 to 2.43; P < 0.001, I2 = 29%; 13 RCTs, 1227 women).
- This suggests that among subfertile women with an expected live birth rate of 19%, the rate among women using antioxidants would be between 24% and 36%.
- Low-quality evidence suggests that antioxidants may improve clinical pregnancy rate compared with placebo or no treatment/standard treatment (OR 1.65, 95% CI 1.43 to 1.89; P < 0.001, I2 = 63%; 35 RCTs, 5165 women).
- This suggests that among subfertile women with an expected clinical pregnancy rate of 19%, the rate among women using antioxidants would be between 25% and 30%.
Morley LC et al. ā¢ The Cochrane database of systematic reviews (2017)
āOur updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low.ā
Key Findings:
- Metformin versus placebo or no treatmentThe evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I2 = 0%, low-quality evidence).
- There was no clear evidence of a difference in miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I2 = 0%, low-quality evidence).
- However, the combined therapy group had higher rates of clinical pregnancy (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I2 = 33%, moderate-quality evidence) and ovulation (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I2 = 64%, moderate-quality evidence).
- Metformin versus clomiphene citrateWhen all studies were combined, findings for live birth were inconclusive and inconsistent (OR 0.71, 95% CI 0.49 to 1.01, 5 studies, 741 women, I2 = 86%, very low-quality evidence).
van der Wel AWT et al. ā¢ JAMA (2025)
āMyo-inositol supplementation during pregnancy did not reduce the incidence of a composite of gestational diabetes, preeclampsia, or preterm birth in patients with PCOS.ā
Key Findings:
- Among 464 participants, the mean (SD) age was 31.5 (3.8) years; 18 participants (3.9%) reported Asian race and 395 (86.1%) reported White race.
- The prevalence of biochemical hyperandrogenism was higher at baseline in the myo-inositol group than the placebo group (29.0% [53 of 180] vs 18.5% [37 of 193]).
- A primary outcome event occurred in 25.0% (nā=ā56) of participants in the myo-inositol group and 26.8% (nā=ā61) in the placebo group (relative risk, 0.93 [95% CI, 0.68-1.28]; Pā=ā.67).
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.